Skip to main content

Home/ Dr. Goodyear/ Group items tagged dosing

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Clinical experience with intravenous administration of ascorbic acid: achievable levels... - 0 views

www.ncbi.nlm.nih.gov/...PMC3751545

IV vitamin C dosing ascorbic acid inflammation disease cancer IV vitamin C intravenous vitamin C IV intravenous vitamin C vitamin C CRP therapy treatment alternative

shared by Nathan Goodyear on 26 Aug 14 - No Cached
  • Patients with higher tumor markers are likely to have higher tumor burden, higher oxidative stress and, therefore, are more likely to have lower post IVC plasma levels.
  • Our data also showed that cancer patients with metastasis tend to have lower post-IVC vitamin C levels than those without metastasis
  • Lower peak plasma concentrations are obtained in cancer patients than in healthy subjects. Cancer patients who are deficient in vitamin C prior to therapy tend to achieve lower plasma levels post infusion.
  • ...25 more annotations...
  • Patients with higher inflammation or tumor burdens, as measured by CRP levels or tumor antigen levels, tend to show lower peak plasma ascorbate levels after IVC.
  • Patients with metastatic tumors tend to achieve lower post infusion plasma ascorbate levels than those with localized tumors.
  • Meta-analyses of clinical studies involving cancer and vitamins also conclude that antioxidant supplementation does not interfere with the efficacy of chemotherapeutic regiments
  • Most of the prostate cancer patients studied, 75±19% (95% confidence), showed reductions in PSA levels during the course of their IVC therapy
  • Laboratory studies suggest that, at high concentrations, ascorbate does not interfere with chemotherapy or irradiation and may enhance efficacy in some situations
  • Cameron and Pauling observed fourfold survival times in terminal cancer patients treated with intravenous ascorbate infusions followed by oral supplementation
  • The inflammatory microenvironment of cancer cells leads to increasing oxidative stress, which apparently depletes vitamin C, resulting in lower plasma ascorbate concentrations in blood samples post IVC infusion. Another explanation for this finding may be that cancers are themselves more metabolically active in their uptake of vitamin C, causing subjects to absorb more of the vitamin, and as a results show lower plasma ascorbate concentrations in blood post IVC infusion.
  • patients with severely elevated CRP levels attain plasma ascorbate concentrations after IVC infusions that are only 65% of those attained for subjects with normal CRP levels
  • The finding of decreased plasma ascorbate levels in cancer patients may relate to the molecular structure of ascorbic acid; in particular, the similarity of its oxidized form, dihydroascorbic acid, to glucose
  • Since tumor have increased requirement for glucose [67], transport of dehydroascorbate into the cancer cells via glucose transport molecules and ascorbate through sodium-dependent transporter may be elevated
  • Increased accumulation of ascorbic acid in the tumor site was supported by measurements of the level of ascorbic acid in tumors in animal experiments
  • patients with advanced malignancies may have lower level of ascorbic acid in tissue, creating a higher demand for the vitamin C
  • IVC therapy appears to reduce CRP levels in cancer patients.
  • CRP concentrations directly correlate with disease activity in many cases and can contribute to disease progression through a range of pro-inflammatory properties.
  • Being an exquisitely sensitive marker of systemic inflammation and tissue damage, CRP is very useful in screening for organic disease and monitoring treatment responses
  • ncreases in CRP concentrations have been associated with poorer prognosis of survival in cancer patients, particularly with advance disease independent of tumor stage
  • Regarding inflammation, 73±13% of subjects (95% confidence) showed a reduction in CRP levels during therapy. This was an even more dramatic 86±13% (95% confidence) in subjects who started therapy with CRP levels above 10 mg/L
  • patients treated by IVC with follow-up several year showed that suppression of inflammation in cancer patients by high-dose IVC is feasible and potentially beneficial
  • Inflammation is a marker of high cancer risk, and poor treatment outcome
  • The subjects with highly elevated CRP concentrations have a three-fold elevation “all-cause” mortality risk and a twenty-eight fold increase in cancer mortality risk
  • cancer patients may need higher doses to achieve a given plasma concentration.
  • patients with lower vitamin C levels may see more distribution of intravenously administered ascorbate into tissues and thus attain less in plasma.
  • When treating patients with IVC, the first treatment likely serves to replenish depleted tissue stores, if those subjects were vitamin C deficient at the beginning of the treatment. Then, in subsequent treatments, with increasing doses, higher plasma concentrations can be attained. On-going treatments serve to progressively reduce oxidative stress in cancer patients.
  • large doses given intravenously may result in maximum plasma concentrations of roughly 30 mM, a level that has been shown to be sufficient for preferential cytotoxicity against cancer cells
  • oral intake of vitamin C exceeded 200 mg administered once daily, it was difficult to increase plasma and tissue concentrations above roughly 200 μM.
  • Nathan Goodyear on 26 Aug 14
     
    Great review on the use of IV vitamin C in cancer and to reduce inflammation.  The article does a great job of discussing the mechanism of vitamin C therapy in cancer as well as the proposed reasons for low vitamin C in cancer patients.  The study also highlights the obstacles to rise in vitamin C levels post IV vitamin C in cancer patients.
Nathan Goodyear

Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential... - 1 views

www.ncbi.nlm.nih.gov/...8023699

IL-2 melatonin immunotherapy cancer

shared by Nathan Goodyear on 31 May 18 - No Cached
  • Nathan Goodyear on 31 May 18
     
    high dose melatonin and low-dose IL-2 in wide variety of solid tumors found tumor regression in 17 of 82 patiens (21%).  Four of these were complete remission and 13 were Partial.
Nathan Goodyear

Low-Dose Naltrexone in Combination with High-Dose Vitamin C in Cancer Patients: Our Exp... - 0 views

LDN metastasis IV vitamin C vitamin C cancer High dose IV vitamin C dose high dose vitamin C low naltrexone)

shared by Nathan Goodyear on 09 Mar 21 - No Cached
  • Nathan Goodyear on 09 Mar 21
     
    Review of one clinics experience with HDIVC and LDN.
Nathan Goodyear

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces susta... - 0 views

www.ncbi.nlm.nih.gov/...PMC517491

angiogenesis VEGF low-dose chemotherapy metronomic chemotherapy

shared by Nathan Goodyear on 24 Aug 20 - No Cached
  • Nathan Goodyear on 24 Aug 20
     
    Low-dose vinblastine found to be anti-angiogenic.
Nathan Goodyear

High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced ... - 1 views

ar.iiarjournals.org/...809.long

IV vitamin C IV vitamin C therapy antioxidant antioxidants cancer

shared by Nathan Goodyear on 25 Sep 13 - No Cached
  • Nathan Goodyear on 25 Sep 13
     
    IV vitamin C dosing shown to be safe and effective.  The levels achieved by IV therapy supercedes that able to achieve by oral therapy by several factors.  This review of the data in this study is of high dose IV vitamin C--safety is reassured.
Nathan Goodyear

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Do... - 0 views

cancerres.aacrjournals.org/...6717

low-dose chemotherapy cancer metronomic chemotherapy

shared by Nathan Goodyear on 03 Jul 20 - No Cached
  • Nathan Goodyear on 03 Jul 20
     
    In many ways, it can be said that low-dose metronomic chemotherapy outperforms maximum tolerated chemotherapy.
Nathan Goodyear

Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on th... - 0 views

maximum tolerated chemotherapy low-dose chemotherapy metronomic chemotherapy

shared by Nathan Goodyear on 04 Oct 20 - No Cached
  • Nathan Goodyear on 04 Oct 20
     
    Only pdf available here. Start difference in the MTD to metronomic dosing of chemotherapy.
Nathan Goodyear

Impact of high dose vitamin C on platelet function - 0 views

www.ncbi.nlm.nih.gov/...PMC5295168

vitamin C platelets High dose IV vitamin C high dose vitamin C

shared by Nathan Goodyear on 22 Nov 21 - No Cached
  • Nathan Goodyear on 22 Nov 21
     
    High dose vitamin C decreases platelet agglutination.
Nathan Goodyear

Low-Dose Naltrexone Reduces the Symptoms of Fibromyalgia - Stanford Systems Neuroscienc... - 0 views

snapl.stanford.edu/...ldn.html

low dose naltrexone LND pain inflammation fibromyalgia stanford

shared by Nathan Goodyear on 27 Nov 12 - No Cached
  • Nathan Goodyear on 27 Nov 12
     
    low dose naltrexone shown to reduce pain in those with fibromyalgia.  This is a very small study, though with positive results.
Nathan Goodyear

Acute prooxidant effects of vitamin C in... [Free Radic Biol Med. 2005] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...15917185

IV vitamin C antioxidant pro-oxidant EDTA EDTA chelation vitamin C vitamin

shared by Nathan Goodyear on 05 Jun 13 - No Cached
  • Nathan Goodyear on 05 Jun 13
     
    This study found a pro oxidant effect of the addition of 5 grams of IV vitamin C with EDTA chelation.  As dosing of IV vitamin C goes, 5 grams is quite small.  Vitamin C has been shown to have varying effects (pro oxidant versus antioxidant) dictated by the dosage.  One wonders if higher dosing IV vitamin C provides antioxidant effects?
Nathan Goodyear

Xanthohumol, a chalcon derived from hops, ... [Mol Nutr Food Res. 2010] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...20087858

xanthohumol NF-KappaB inflammation liver NAFLD

shared by Nathan Goodyear on 03 Jan 13 - No Cached
  • Nathan Goodyear on 03 Jan 13
     
    xanthohumol again shows to inhibit NF-kappaB.  This time in individuals with NAFLD and chronic liver disease.  The effect was shwon to be dose dependent, without plateau with dosing up to 50 Mcriomoloar
Nathan Goodyear

The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer - 0 views

www.jacn.org/...118.full.pdf

IV IV vitamin C vitamin C ovarian cancer ovarian cancer antioxidants

shared by Nathan Goodyear on 30 Jan 13 - No Cached
  • Nathan Goodyear on 30 Jan 13
     
    IV, high dose, vitamin C adjunct therapy shown to aid in the remission in to women with ovarian cancer. These two cases studies do only looked and high dose antioxidant therapy as an adjunct in ovarian cancer and they found good results.
Nathan Goodyear

Delayed Neuroendocrine Sexual Maturation in Female Rats After a Very Low Dose of Bisphe... - 0 views

press.endocrine.org/...en.2015-1937

BPA toxins environmental toxins xenoextrogens bisphenol A hormones

shared by Nathan Goodyear on 18 May 16 - No Cached
  • Nathan Goodyear on 18 May 16
     
    low dose of BPA in rat model finds delayed sexual maturation.
Nathan Goodyear

Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized c... - 0 views

ajcn.nutrition.org/...1079.long

blood pressure hypertension vitamin C

shared by Nathan Goodyear on 16 Jan 17 - No Cached
  • Nathan Goodyear on 16 Jan 17
     
    review article of 29 studies finds a reduction in blood pressure with vitamin C.  The average dosing of vitamin C was 500 mg, which is a woefully inadequate dose.  The average study follow up was 8 weeks.
Nathan Goodyear

Vitamins E and C are safe across a broad range of intakes - 0 views

ajcn.nutrition.org/...736.long

vitamins vitamin E vitamin C alternative medicine

shared by Nathan Goodyear on 13 Jun 16 - No Cached
  • Nathan Goodyear on 13 Jun 16
     
    high dose vitamin E and vitamin C are found to be safe.  As always, the majority of these studies did not include pre-treatment vitamin assessment to ensure a metabolic need.  To much of a good thing can be a bad thing.  Also, higher dosing of vitamins approach a medicinal use and an associated increase in side effects.
Nathan Goodyear

[Effects of testosterone on insulin r... [Zhonghua Yi Xue Za Zhi. 2006] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...16842700

low T testosterone GLUT4 insulin IRS-1

shared by Nathan Goodyear on 12 Feb 12 - No Cached
  • Nathan Goodyear on 12 Feb 12
     
    Testosterone shown to improve GLUT 4 and IRS-1 expression with low dose short term therapy; in contrast, high dose, prolonged therapy shown to down regulate IRS-1 and GLUT 4 expression.  This shows the importance of using saliva for evaluation versus serum.  Serum testing routinely leads to over treatment with high dosages of testosterone.
Nathan Goodyear

Adverse Events Associated with Testosterone Administration - NEJM - 0 views

www.nejm.org/...NEJMoa1000485

Testosterone therapy low T treatment men male hormone hormones

shared by Nathan Goodyear on 31 Jan 14 - No Cached
  • Nathan Goodyear on 31 Jan 14
     
    Study of 209 men > 65 on Testosterone therapy was stopped early due to increase cardiovascular adverse events  The likely reason was the amazingly high dosing.  The men in this study were just doped.  The dosing was 100 mg + which is in stark contrast to the 5-10 mg daily production of a young man at 22.
Nathan Goodyear

http://onlinelibrary.wiley.com/store/10.1002/hep.21080/asset/21080_ftp.pdf;jsessionid=C... - 0 views

onlinelibrary.wiley.com/...FD1E43279D6DC7447C7FC1A.f04t01

vitamin C IV vitamin C IV intravenous cirrhosis

shared by Nathan Goodyear on 10 Feb 14 - No Cached
  • Nathan Goodyear on 10 Feb 14
     
    small study looked at patients with liver cirrhosis.  The authors used a low dose of IV vitamin C (5 grams) and found that this improved endothelial dysfunction.  Patients with cirrhosis were found to be low in vitamin C.  The IV vitamin C was well tolerated, despite a low dose.
Nathan Goodyear

Testosterone, SHBG and cardiovascular health in postmenopausal women - 0 views

dspace.library.uu.nl/...39518

Testosterone women female hormone hormones CVD cardiovascular disease

shared by Nathan Goodyear on 20 Mar 14 - No Cached
  • Nathan Goodyear on 20 Mar 14
     
    Master's thesis reviews Testosterone therapy in women.  The evidence is poor.  What is seen is that low SHBG and increasing Testosterone in the long term appears to be associated with adverse CV effects. Otherwise, the effects of Testosterone are negligible if negative at all.   High dose studies did find increased CVD in women. The dosing here was at 40 mg.
« First ‹ Previous 41 - 60 of 676 Next › Last »
Showing 20▼ items per page